Experience

EpiBiologics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Feb 2023 - 11 months

  San Francisco Bay Area



Seagen

• United States
• Biotechnology Research
• 700 & Above Employee

• Vice President of Therapeutic Discovery Research

  • Nov 2021 - Feb 2023

  Bothell, Washington, United States

• Executive Director Immunology

  • Jan 2020 - Nov 2021

  Bothell, Washington Tenure focused on identifying novel and innovative ways to battle cancer; responsible for initiating the discovery and delivery of a pipeline of diverse Phase 1 candidates, including SEA-CD40, SGN-2FF, SGN-CD47M, SEA-TGT, and SGN-B7H4V that incorporate known ADC linkers, novel chemistry and protein engineering technologies; prepared regulatory documents and interacted with US and European regulatory agencies to support early and late stage clinical programs; discovered novel immune modulatory… Show more Tenure focused on identifying novel and innovative ways to battle cancer; responsible for initiating the discovery and delivery of a pipeline of diverse Phase 1 candidates, including SEA-CD40, SGN-2FF, SGN-CD47M, SEA-TGT, and SGN-B7H4V that incorporate known ADC linkers, novel chemistry and protein engineering technologies; prepared regulatory documents and interacted with US and European regulatory agencies to support early and late stage clinical programs; discovered novel immune modulatory activity of existing ADC clinical stage assets which transformed the clinical opportunities for these molecules; built, lead, and set the strategy for the immunology research team within Seagen; member of the broader research leadership team accountable for crafting the scientific strategy for research; worked with business development to evaluate and successfully in-license three distinct molecular assets that have been incorporated into clinical candidates; led multiple cross-functional initiatives including deploying an educational series for research associates, incorporating DEI principles into the research organization, and reworking the rewards and recognition process; presented at multiple high impact external speaking events including Seagen’s 2020 R&D day.

• Principal Scientist 2013-15; Associate Director 2015-16; Director 2016-18; Senior Director 2018-19

  • Dec 2013 - Dec 2019

  Seattle, Washington



Second Genome Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Associate Director

  • May 2013 - Dec 2013

  San Francisco Bay Area Developed strategies for assessing the influence of the microbiome on inflammatory and metabolic disease; led the discovery research team which involved establishing cellular and organotypic models to investigate microbiome causality in inflammatory and metabolic disease areas; key opinion leader involved in evaluating multiple in-licensing opportunities.



Elan Pharmaceuticals

• Ireland
• Biotechnology
• 300 - 400 Employee

• Principal Scientist, 2011-2012; Staff Scientist, 2009-2011; Scientist, 2006-2009

  • Oct 2006 - Dec 2012

  South San Francisco, CA Conceived and directed multiple discovery projects focused on identifying novel targets for the treatment of Multiple Sclerosis and Parkinson’s disease, efforts resulted in development of antibody and small molecule therapeutics, biomarkers of disease, high impact publications, and patent filings; led projects requiring novel assay development for the identification of antibodies and small molecules as therapeutics for neurodegenerative diseases; utilized molecular and proteomic techniques in… Show more Conceived and directed multiple discovery projects focused on identifying novel targets for the treatment of Multiple Sclerosis and Parkinson’s disease, efforts resulted in development of antibody and small molecule therapeutics, biomarkers of disease, high impact publications, and patent filings; led projects requiring novel assay development for the identification of antibodies and small molecules as therapeutics for neurodegenerative diseases; utilized molecular and proteomic techniques in combination with bioinformatics to identify novel targets and biomarkers; fostered multiple academic collaborations; guided a research team which, contributed to an IND filing focused on Alzheimer disease; managed a team comprised of junior and senior scientists Show less



JANSSEN Alzheimer Immunotherapy

• United States

• Principal Scientist

  • Jan 2009 - Nov 2012

  South San Francisco



University of Colorado Heath Science Center

• Research Services
• 300 - 400 Employee

• Instructor

  • Sep 2005 - Oct 2006

  Denver, Colorado Originated and developed the concept that CD47 (integrity-associated protein) on viable cells interacts with SIRP-α (SHPS-1) on phagocytes and prevents inadvertent removal, and that surface calretuculin is required for efficient removal of apoptotic cells (Cell, 2005); received the Atorvastatin Research Award focused on defective inflammation and apoptotic cell clearance in diabetic mice and the possible therapeutic role of statins; established myself as a notable individual in the field of… Show more Originated and developed the concept that CD47 (integrity-associated protein) on viable cells interacts with SIRP-α (SHPS-1) on phagocytes and prevents inadvertent removal, and that surface calretuculin is required for efficient removal of apoptotic cells (Cell, 2005); received the Atorvastatin Research Award focused on defective inflammation and apoptotic cell clearance in diabetic mice and the possible therapeutic role of statins; established myself as a notable individual in the field of inflammation and macrophage biology as illustrated by invitations to speak at national and international conferences; supervised and trained pulmonary medical fellows, postdoctoral fellows, and graduate students. Show less



National Jewish Medical and Research Center

• United States
• Medical Practices

• Postdoctoral Fellow

  • May 2002 - Sep 2005

  Denver, Colorado Elucidated the dual nature of the lung surfactant proteins SP-A and SP-D by discovering that these proteins enhance or suppress inflammation depending on binding orientation, (Cell, 2003); initiated a clinical aging study focused on inflammation that required the recruitment and continued management of young and elderly human patients.



University of Colorado Health Sciences Center

• Research Services
• 300 - 400 Employee

• Graduate Student

  • Jan 1997 - Jan 2002

  Denver, Colorado Performed a comprehensive analysis of the signaling pathways that regulate neutrophil apoptosis; characterized the ability of anti-apoptotic stimuli to protect neutrophils from stress-induced apoptosis, (JBC, 2004); made substantial advancements in understanding the dual role of beta-2 integrins on the inflammatory process and neutrophil apoptosis, (JCB, 2000); developed and honed numerous skills in histology, pathology, molecular biology, immunology, and cell biology via a combination of… Show more Performed a comprehensive analysis of the signaling pathways that regulate neutrophil apoptosis; characterized the ability of anti-apoptotic stimuli to protect neutrophils from stress-induced apoptosis, (JBC, 2004); made substantial advancements in understanding the dual role of beta-2 integrins on the inflammatory process and neutrophil apoptosis, (JCB, 2000); developed and honed numerous skills in histology, pathology, molecular biology, immunology, and cell biology via a combination of formal course work and practical application; participated and received awards in a university sponsored research forum for three consecutive years. Show less